T. Muranaka

The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study

Introduction Irinotecan is a key drug for advanced gastric cancer (AGC). We previously reported that patients with UGT1A1 single heterozygous (SH) had a significantly high frequency of s...

T. Miyagishima ;

A. Tanimoto ;

S. Yuki ;

T. Honda ;

Y. Komatsu ;

Y. Kobayashi ;

T. Sasaki ;

Y. Kawamoto ;

A. Ishiguro ;

K. Hatanaka ;

M. Dazai ;

H. Nakatsumi ;

Tomo Ando , MD;

H. Yoshita ;

S. Nakano ;

K. Sawada ;

T. Muranaka ;

K. Harada ;

07/01/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

T. Muranaka

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products